company? Let’s change
that.
Don't see your company?
Create a company profileBecker Underwood is the global leader in the development & commercialization of value-creating seed-applied biological products.
Sisu is a medical device company that designs and commercializes medical devices with and for emerging markets.
BioForce Nanosciences, Inc. develops and commercializes nanotech instruments, consumables, and applications for the life sciences.
To advance the science of medical cannabis and help patients who suffer from chronic pain and debilitating diseases.
At Karuna, our purpose is to create and deliver transformative medicines for people living with psychiatric and neurological conditions. Through the cultivation of our deep expertise in neuroscience, and inventive thinking around drug discovery and development, we are advancing a pipeline of novel medicines with the goal of providing a meaningful difference in the lives of those affected by these conditions. Our culture is defined by our passion to serve those affected by mental illness. We are purpose-driven and intentional. We know impactful innovations don’t come easy, but are borne from passion and hard work. Together, we are working toward a goal bigger than ourselves.
OncoFusion Therapeutics is engaged in the R&D of personalized therapeutics for patients with genetically defined cancers.
TapImmune develops immunotherapeutics to treat cancers, infectious diseases, autoimmune disorders, and transplant tissue rejection.
Kinnate Biopharma develops precision oncology therapeutics to treat patients with genomically-defined cancers.
Purple Communications provides communication services for people who are deaf or find it difficult to hear in the U.S.
We Focus on Identifying, Acquiring and Developing Disease-Modifying Therapeutic Drug Candidates with Rare Disease Indications
CARI Health is developing the next generation of Remote Medication Monitors that will allow clinicians to prescribe medications and receive real-time reporting on medication levels. CARI’s small, wireless sensors are worn on the patient’s skin and continuously monitor medication levels, sending alerts when necessary. With a CARI Remote Medication Monitor clinicians can provide precision care in this new era of telehealth medicine.
Immunicom is a biotechnology company.
Autobahn Therapeutics is a developer of regenerative medicines to restore hope for people affected by CNS disorders.
Applied Molecular Therapeutics (AMT), a public biopharmaceutical company based in South San Francisco, California, is committed to developing novel, oral biological therapeutics to treat severe autoimmune, metabolic and inflammatory diseases. AMT is leveraging its propriety technology platforms to create gastrointestinal (GI)-select therapeutics that harness naturally occurring transport and targeting mechanisms to cross the protective barrier of the intestinal epithelium (IE). Once across the IE, the therapeutics gain privileged access to the immune cell-rich environment of the GI tissue as well as the hepatic portal system and downstream systemic circulation. With this privileged access, AMT’s goal is to develop transformative new oral therapeutic treatment options that offer patients greater efficacy and tolerability than available with today’s therapeutics. AMT has a robust pipeline of oral biologic product opportunities, including AMT-101 which is currently in Phase 1b clinical development for the treatment of adults with ulcerative colitis (UC). AMT-101 is a novel, gut-selective, investigational oral biologic fusion protein of interleukin 10 (IL-10), an anti-inflammatory cytokine. Derived from AMT’s proprietary platforms, AMT-101 is engineered to cross the selective barrier of the IE and enhance localized IL-10 directly within the immune-cell rich environment of GI tissue where up to 75 percent of immune cells reside. This direct targeting of the immune system creates the potential for AMT-101 to address, at its point of origin, the immune dysregulation that gives rise to UC and other inflammatory bowel diseases, and restore immune homeostasis with minimal systemic exposure and potentially fewer adverse events compared to systemic administration of IL-10. AMT has amassed a broad global IP portfolio surrounding its multiple technology platforms and therapeutic programs.
ShapeTX is pioneering the field of programmable RNA medicines to repair the genetic causes of diseases. By merging innovations in AI and RNA technology to generate and analyze hundreds of billions of therapeutic possibilities, ShapeTX is developing breakthroughs in RNA editing, next-generation AAVs, and disruptive gene therapy manufacturing. The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer’s, Parkinson’s, and many more.
Singular Genomics is a venture capital backed biotech company in La Jolla, California. We foster a dynamic, fast paced, result oriented environment where we offer employees the opportunity to make a significant impact in a rapidly expanding company. Singular Genomics is inventing at the forefront of genomics, one of the world’s fastest growing industries. We are located in the center of the Biotech hub on the Torrey Mesa close to the Pacific Ocean and next door to prestigious institutions like the Salk Institute, Scripps, Sanford Burnham, and UCSD. We offer free gym membership, 401K plan, competitive health benefits, flexible vacation, and equity incentives, so you can grow as the company grows. We are working to accelerate genomics for the advancement of science and medicine and are passionate about the potential of genomics for improving human health.
MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™, and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.
UCB – Inspired by patients. Driven by science. At UCB, we put our heart, soul and skills into making a difference for people living with severe diseases. We look to transform patients’ lives by pushing the boundaries of what is possible. With us, our talents makes the most of who they are, unlocking innovation and setting new standards for patients. Everything we do starts with a simple question: “How will this make a difference to the lives of people living with severe diseases?” And to find the answers, we connect globally with patients and their families living with the physical and social burdens of severe disease. These connections give us new perspectives, drive our innovation, and offer a hope for a new generation of therapies that will help to transform lives. UCB – The Facts With more than 8500 employees in approximately 40 countries, we are a global biopharmaceutical company headquartered in Brussels, Belgium which invests more than 25% of revenue in cutting-edge scientific research to meet unmet patient needs. A few other reasons that make UCB an amazing place to work: - Promising pipeline that includes several novel molecules; - 2021 Key Financials: €5.8 billion global revenue Specialties: Neurology, Immunology
OpenCell Technologies provides efficient, high-throughput and scalable transfection tools to researchers in the Life Sciences.
At Athelas, we're bringing simple, life-changing health care products to people around the globe. The future of healthcare is at the home - we are a team of technologists building the next generation of medical products at the intersection of hardware and software. We won’t stop until we’ve brought the world class tools of a hospital to your home. Athelas Remote Patient Monitoring (RPM) allows healthcare providers to monitor patient vitals like blood pressure, weight, and blood glucose without the patient ever having to enter a clinic, improving patient health and engagement, and reducing hospitalizations. We do this all through a beautifully integrated suite of devices and software tools that provides access to state-of-the-art technologies and groundbreaking AI powered analysis.